During the past decade, Niigata Cancer Center Hospital conducted 74 clinical trials. In the 10-year time frame, 74 clinical trials started and 35 clinical trials were completed, i.e. on average, 47.3% percent of trials that started reached the finish line to date. In the past 5 years, 36 clinical trials started and 27 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Niigata Cancer Center Hospital" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Janssen Research & Development, LLC" with 9 trials sponsored, "Amgen" with 8 trials sponsored, "Haruhiko Fukuda" with 8 trials sponsored and "Pfizer" with 8 trials sponsored. Other sponsors include 54 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Niigata Cancer Center Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 12 trials as a collaborator, "AstraZeneca" with 6 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "NSABP Foundation Inc" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Niigata Cancer Center Hospital" are "Carcinoma, Non-Small-Cell Lung" (11 trials), "Breast Cancer" (8 trials), "Multiple Myeloma" (8 trials), "Non-Small Cell Lung Cancer" (4 trials) and "Breast Neoplasms" (3 trials). Many other conditions were trialed in "Niigata Cancer Center Hospital" in a lesser frequency.

Most popular intervention types in "Niigata Cancer Center Hospital" are "Drug" (102 trials), "Procedure" (9 trials), "Biological" (5 trials), "Other" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Paclitaxel" (10 trials), "Carboplatin" (9 trials), "Pemetrexed" (9 trials) and "Atezolizumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Niigata Cancer Center Hospital" are 92 trials for "All" genders, 15 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Niigata Cancer Center Hospital". undefined are not yet recruiting, 25 are recruiting, 28 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Niigata Cancer Center Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Niigata Cancer Center Hospital, 11 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 75 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".